Judith Cave

3.4k total citations
35 papers, 675 citations indexed

About

Judith Cave is a scholar working on Oncology, Epidemiology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Judith Cave has authored 35 papers receiving a total of 675 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 18 papers in Epidemiology and 9 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Judith Cave's work include Lung Cancer Research Studies (19 papers), Neuroendocrine Tumor Research Advances (17 papers) and Neuroblastoma Research and Treatments (7 papers). Judith Cave is often cited by papers focused on Lung Cancer Research Studies (19 papers), Neuroendocrine Tumor Research Advances (17 papers) and Neuroblastoma Research and Treatments (7 papers). Judith Cave collaborates with scholars based in United Kingdom, Italy and Germany. Judith Cave's co-authors include Katherine Woolf, Jane Dacre, Alison Jones, Trisha Greenhalgh, Christian H. Ottensmeier, Trevor W Lambert, Michael J Goldacre, Michael P. W. Grocott, Sandy Jack and Malcolm West and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Judith Cave

34 papers receiving 658 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Judith Cave United Kingdom	12	334	241	188	73	70	35	675
Sarah Liptrott Italy	11	180 0.5×	274 1.1×	37 0.2×	14 0.2×	30 0.4×	47	548
Sarah Bean United States	12	360 1.1×	90 0.4×	211 1.1×	13 0.2×	168 2.4×	22	905
Noha Sharafeldin United States	11	159 0.5×	65 0.3×	28 0.1×	19 0.3×	85 1.2×	29	497
Patricia J. Numann United States	14	202 0.6×	125 0.5×	67 0.4×	9 0.1×	68 1.0×	36	806
Kate V. Viola United States	11	115 0.3×	266 1.1×	102 0.5×	11 0.2×	26 0.4×	17	717
Livia Giordano Italy	17	686 2.1×	150 0.6×	317 1.7×	16 0.2×	99 1.4×	76	1.0k
Luke Mounce United Kingdom	16	193 0.6×	65 0.3×	250 1.3×	32 0.4×	103 1.5×	49	675
Stela Verzinhasse Peres Brazil	14	191 0.6×	168 0.7×	73 0.4×	31 0.4×	145 2.1×	64	611
Dori Klemanski United States	13	503 1.5×	143 0.6×	191 1.0×	127 1.7×	123 1.8×	23	807
Jeffrey D. Hord United States	15	83 0.2×	95 0.4×	50 0.3×	9 0.1×	42 0.6×	34	568

Countries citing papers authored by Judith Cave

Since Specialization

Citations

This map shows the geographic impact of Judith Cave's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Judith Cave with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Judith Cave more than expected).

Fields of papers citing papers by Judith Cave

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Judith Cave. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Judith Cave. The network helps show where Judith Cave may publish in the future.

Co-authorship network of co-authors of Judith Cave

This figure shows the co-authorship network connecting the top 25 collaborators of Judith Cave. A scholar is included among the top collaborators of Judith Cave based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Judith Cave. Judith Cave is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Behrouzi, Roya, Alessio Signori, Judith Cave, et al.. (2023). Immunotherapy-related adverse events in real-world patients with advanced non-small cell lung cancer on chemoimmunotherapy: a Spinnaker study sub-analysis. Frontiers in Oncology. 13. 6 indexed citations

Behrouzi, Roya, Alessio Signori, Judith Cave, et al.. (2023). The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study. International Journal of Molecular Sciences. 24(2). 1746–1746. 3 indexed citations

McNamara, Mairéad G., Rohini Sharma, Olusola Olusesan Faluyi, et al.. (2023). NET-02 final results: A randomised, phase II trial of liposomal irinotecan (nal-IRI)/5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line (2L) therapy in patients (pts) with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (PD-EP-NEC).. Journal of Clinical Oncology. 41(4_suppl). 646–646.

Fennell, Dean A., Daniel E. Griffiths, Zina Eminton, et al.. (2023). Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. BMJ Open. 13(11). e073120–e073120. 2 indexed citations

Pattini, Linda, Neil W. Pearce, Eleanor Jaynes, et al.. (2022). Utility of KI-67 as a prognostic biomarker in pulmonary neuroendocrine neoplasms: a systematic review and meta-analysis. BMJ Open. 12(3). e041961–e041961. 9 indexed citations

Banna, Giuseppe Luigi, Ornella Cantale, S. Muthuramalingam, et al.. (2022). Efficacy outcomes and prognostic factors from real-world patients with advanced non-small-cell lung cancer treated with first-line chemoimmunotherapy: The Spinnaker retrospective study. International Immunopharmacology. 110. 108985–108985. 21 indexed citations

Machado, Maria do Céu, Margaret Ashton‐Key, Serena Chee, et al.. (2021). Analysis of Immune Landscape in Pancreatic and Ileal Neuroendocrine Tumours Demonstrates an Immune Cold Tumour Microenvironment. Neuroendocrinology. 112(4). 370–383. 11 indexed citations

Wadsley, Jonathan, Nicholas S. Reed, Olusola Olusesan Faluyi, et al.. (2020). NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open. 10(2). e034527–e034527. 13 indexed citations

Middleton, Gary, Sanjay Popat, Yvonne Summers, et al.. (2019). PL02.09 National Lung Matrix Trial (NLMT): First Results from an Umbrella Phase II Trial in Advanced Non-Small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology. 14(10). S7–S7. 1 indexed citations

10.

Jaynes, Eleanor, et al.. (2019). The utility of Ki-67 as a prognostic biomarker in pulmonary neuroendocrine tumours: protocol for a systematic review and meta-analysis. BMJ Open. 9(8). e031531–e031531. 11 indexed citations

11.

Cave, Judith, et al.. (2018). A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Supportive Care in Cancer. 26(10). 3337–3351. 42 indexed citations

12.

Ramage, John, Olusola Olusesan Faluyi, Andrea Frilling, et al.. (2016). UK phase IV, observational study to assess quality of life in patients (pts) with pancreatic neuroendocrine tumours (pNETS) receiving treatment with everolimus: The “real-world” OBLIQUE study. Annals of Oncology. 27. vi143–vi143. 1 indexed citations

13.

Cave, Judith. (2016). Oncology and medical education—past, present and future. ecancermedicalscience. 10. ed54–ed54. 5 indexed citations

14.

Arriola, Edurne, Matthew Wheater, Ian Galea, et al.. (2016). Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. Journal of Thoracic Oncology. 11(9). 1511–1521. 97 indexed citations

15.

Ewings, Sean, Eleanor Jaynes, Sarah Ellis, et al.. (2015). The assessment of Ki-67 as a prognostic marker in neuroendocrine tumours: a systematic review and meta-analysis. Journal of Clinical Pathology. 69(7). 612–618. 47 indexed citations

16.

Crabb, Simon J., Luke Nolan, S. Muthuramalingam, et al.. (2012). A Phase I Clinical Trial of Irinotecan and Carboplatin in Patients with Extensive Stage Small Cell Lung Cancer. Chemotherapy. 58(4). 257–263. 5 indexed citations

17.

Cave, Judith, Katherine Woolf, Alison Jones, & Jane Dacre. (2009). Easing the transition from student to doctor: How can medical schools help prepare their graduates for starting work?. Medical Teacher. 31(5). 403–408. 76 indexed citations

18.

Gill, Deborah, Ann Griffin, Katherine Woolf, & Judith Cave. (2009). Twelve tips for studying medical education at doctoral level. Medical Teacher. 31(7). 601–604. 10 indexed citations

19.

Woolf, Katherine, Judith Cave, Trisha Greenhalgh, & Jane Dacre. (2008). Ethnic stereotypes and the underachievement of UK medical students from ethnic minorities: qualitative study. BMJ. 337(aug18 1). a1220–a1220. 92 indexed citations

20.

Cave, Judith, Michael J Goldacre, Trevor W Lambert, et al.. (2007). Newly qualified doctors' views about whether their medical school had trained them well: questionnaire surveys. BMC Medical Education. 7(1). 38–38. 76 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact